With paltusotine, we’re developing a once-daily pill for acromegaly that may replace the life-disrupting process of getting an injection every month or needing to follow a strict daily schedule for short-acting octreotide. Now in Phase 3, a once-daily oral therapy will be a welcome development for patients and could solve for a real market need. And there’s plenty more where that came from. Read on for our latest advancements and the market opportunities they hold for investment in our focused area of endocrinology pharmaceuticals.
Events
Dec 18, 2023 at 5:00 PM EST
Sep 11, 2023 at 8:00 AM EDT
Aug 8, 2023 at 12:00 PM EDT
Press Releases
April 11, 2024
Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 19, 2024
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
March 12, 2024
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
Dive deeper into Crinetics, the market needs we address, our pipeline and candidate drugs, clinical trials, and more.
Investor Resources
Data Provided by Refinitiv. Minimum 15 minutes delayed.